CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Venetoclax
Back to Programs and Services

CADTH Reimbursement Review

Venetoclax

Last Updated: January 13, 2021
Result type: Reports
Project Number: PC0238-000
Product Line: Reimbursement Review

Generic Name: Venetoclax

Brand Name: Venclexta

Manufacturer: AbbVie Corporation

Therapeutic Area: Acute myeloid leukemia

Indications: Venclexta is indicated, in combination with a hypomethylating agent or in combination with low-dose cytarabine, in adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Manufacturer Requested Reimbursement Criteria1: In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Submission Type: Initial

Tumour Type: Leukemia

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openDecember 03, 2020
Call for patient/clinician input closedJanuary 29, 2021
Submission receivedJanuary 08, 2021
Submission accepted-
Submit Feedback